The Combination Effect of Citicoline and Omega-3

This study is a randomized, double-blind, placebo-controlled trial. The investigators hypothesize that supplementation of Citicoline plus Omega-3 will improve attention in healthy adults age 55 years and older, compared to placebo. The study is designed as 3-arm, parallel group study comparing placebo, Omega-3 only, and Citicoline plus Omega-3.

• Placebo supplement (Dietary supplement), also known as Placebo: Cellulose and Sunflower oil
• Citicoline and Omega-3 supplement (Dietary supplement), also known as Cognizin and Omega-3: Citicoline and Omega-3
• Omega-3 supplement (Dietary supplement), also known as Omega-3: Cellulose and Omega-3

Primary outcomes

• Accuracy (percent correct) on an attention task (Conners continuous performance test3) [16 weeks]

Secondary outcomes

• Scores of Neuropsychological test battery from the Uniform Data Set [16 weeks]

Other outcomes

• Number of participants with treatment-related adverse events as monitored by recording a comprehensive metabolic panel, complete blood count and prothrombin time-international normalized ratio [16 weeks]
• Plasma fatty acid levels [16 weeks]
• Apolipoprotein E genotype [Baseline]

Sex: All, ages: 55 Years to any, accepts healthy volunteers

Inclusion Criteria:

* Age 55 years or older
* If female, must be post-menopausal
* Non-demented
* Not depressed
* General health status that will not interfere with the participant's ability to complete the study
* No history of neurological disorder
* Screening laboratory values within normal limits or, if abnormal, deemed clinically insignificant by the investigator
* Sufficient English language skills to complete all testing

Exclusion Criteria:

* Alzheimer's, Dementia or other neurological disease
* Fish intake of 6 ounce serving once a week 3 months prior to enrollment; Omega-3 supplement intake (e.g. fish oil capsules, cod liver oil, or flaxseed oil) less than 3 months prior to enrollment.
* Citicoline supplementation 3 months prior to enrollment
* Prescriptions medications:

  1. Anticoagulation therapy: Vitamin K antagonist: warfarin (Coumadin, jantoven), Factor Xa inhibitors: rivaroxaban (xarelto), fondaparinux (arixtra), dibigatran (pradaxa), apixaban (eliquis); Low molecular weight heparins: dalteparin (fragmin), enoxaparin (lovenox)
  2. Dementia medications (e.g. anticholinesterase inhibitors, memantine)
  3. Diagnosis of Adult Attention Deficit Disorder (ADD) or Attention Deficit Hyperactivity Disorder (ADHD) and/or taking stimulants (e.g. dextroamphetamine sulfate, methylphenidate HCL, dextroamphetamine Sulf-Saccharate)
* Body Mass Index > 30
* Enrollment in another treatment study